Key catalysts to watch: Phase 2 axatilimab data in IPF and cGVHD (both 4Q26), revumenib proof-of-principle trial initiation in MF (4Q26), and IND filings for SNDX-4321 (YE 2026) and SNDX-62122 (2027). The pipeline expansion into NSCLC and MF opens new blockbuster opportunities but adds clinical and regulatory risk. Monitor enrollment timelines and early safety/efficacy signals from the MF proof-of-principle trial.
Drugs in focus
SNDX drug pipeline →Niktimvo
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched (FDA approved August 2024)
- Next catalyst
- None dated
What to watchNiktimvo's commercial trajectory is the primary value driver for SNDX on this drug. Watch Q2/Q3 2026 net revenue prints for signs of continued ramp ($151.6M FY2025 annualizing to ~$220M in Q1 2026). The Phase 2 IPF readout in Q4 2026 is an important optionality catalyst that could open a much larger market, but comes with clinical risk. The $250M convertible note issued June 2026 introduces modest dilution overhang (~8-10% of shares outstanding).
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $24.13entry
- T+1 · 4mo ago −2.53%α −2.92% · $23.52
- T+5 · 4mo ago −7.63%α −6.33% · $22.29
- T+20 · 3mo ago −15.91%α −18.41% · $20.29
- T+60 · 6w ago −29.42%α −32.80% · $17.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Syndax held an R&D event unveiling two new pipeline assets: SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. The company also highlighted upcoming Phase 2 data readouts for axatilimab in IPF (4Q26) and axatilimab + ruxolitinib in cGVHD (4Q26), and reiterated that Revuforj and Niktimvo are annualizing at ~$200M combined as of 1Q26. No financial results were reported; the filing is a strategic pipeline update.
Key Facts
- Unveiled SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC; IND submission expected by YE 2026, Phase 1 in 2027.
- Unveiled SNDX-62122, a next-generation menin inhibitor for myelofibrosis; IND and Phase 1 expected in 2027.
- Phase 1/2 proof-of-principle trial of revumenib in myelofibrosis expected to initiate in 4Q26 with initial data in 2H27.
- Phase 2 MAXPIRe trial of axatilimab in IPF on track for topline data in 4Q26.
- Phase 2 axatilimab + ruxolitinib data in cGVHD expected 4Q26.
- Revuforj and Niktimvo combined annualizing at ~$200M as of 1Q26.
- Company expects to have at least 4 innovative assets in the clinic by 2027.
- SNDX-4321 is an externally developed molecule with exclusive worldwide license; SNDX-62122 is internally developed and wholly owned.
Financial Impact
No financial results reported. Revuforj and Niktimvo combined annualizing at ~$200M as of 1Q26. Company states it is fully funded to advance late-stage trials and pipeline assets.
Risk Factors
- All pipeline assets are preclinical or early-stage; clinical failure risk is high.
- SNDX-4321 faces competition from multiple 4th-gen EGFR inhibitors and bispecific antibodies in development.
- Revumenib MF trial is proof-of-principle; clinical translation of preclinical data is uncertain.
- No financial guidance or revenue figures beyond the ~$200M annualization rate were provided.
- Reliance on partnerships (MPN-RC consortium, Incyte-led trials) introduces execution dependency.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-302608 |
| Document: sndx-20260714.htm | 0001193125-26-302608 |
| Document: sndx-ex99_1.htm | 0001193125-26-302608 |
| Document: 0001193125-26-302608-index-headers.html | 0001193125-26-302608 |
| Document: 0001193125-26-302608-index.html | 0001193125-26-302608 |
| Document: 0001193125-26-302608.txt | 0001193125-26-302608 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Viewing Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers